Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma

Cancer

Volumn 104, Issue 3, 2005, Pages 570-579

  Wagner, Jeffrey D ^a   Schauwecker, Donald ^a   Davidson, Darrell ^a   Logan, Theodore ^a   Coleman III, John J ^a   Hutchins, Gary ^a   Love, Charlene ^a   Wenck, Stacie ^a   Daggy, Joanne ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluorodeoxyglucose; Lymph nodes; Melanoma; Metastases; Positron emission tomography scan

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OCCULT CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE; SINGLE BLIND PROCEDURE; SKIN CANCER; THICKNESS; TUMOR VOLUME; VALIDATION PROCESS;

ADULT; AGED; BIOPSY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 22544441594     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21189     Document Type: Article

References (20)

1. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484-1491.
2. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage 1 or II melanoma patients. J Clin Oncol. 1999;17:976-983.
3. Wagner JD, Ranieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel node biopsy and selective lymphadenectomy for melanoma. Plast Reconst Surg. 2003;112:486-497.
4. Gritters LS, Francis IR, Zasadny KR, et al. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med. 1993;34:1420-1427.
5. Boni R, Boni PJA, Steinert H, et al. Staging of metastatic melanoma by whole body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D- glucose. Br J Dermatol. 1995;132:556-562.
6. Wagner JD, Schauwecker D, Hutchins G, et al. Initial assessment of positron emission tomography for detection of subclinical regional lymphatic metastases in melanoma. J Surg Oncol. 1997;64:181-189.
7. Steinert HC, Boni RA, Buck A, et al. Malignant melanoma: staging with whole body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology. 1995;195:705-709.
8. Rinne D, Baum RP, Hor G, et al. Primary staging and followup of high-risk melanoma patients with whole body 18 F-fluorodeoxyglucose positron emission tomography. Results of a prospective study of 100 patients. Cancer. 1998;82:1664-1671.
9. Kirgan D, Guenther J, Bhattathiry M, et al. The importance of whole body PET scans on the management of metastatic malignant melanoma [abstract]. Proc Am Soc Clin Oncol. 1994;13:396.
10. Blessing C, Feine U, Geiger L, et al. Positron emission tomography and ultrasonography: a comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol. 1995;131:1394-1398.
11. Damian DL, Fulham MJ, Thompson E, et al. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325-329.
12. Macfarlane DJ, Sondak V, Johnson T, Wahl R. Prospective evaluation of 2-(18F)-2-deoxyglucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol. 1998;16:1770-1776.
13. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma: clinical utility in patients with stage III disease. Cancer. 2000;89:1019-1025.
14. Mijnhout SG, Hoekstra OS, van Tulter MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of 18 f-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530-1542.
15. Wagner JD, Schauwecker DS, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999;17:1508-1515.
16. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
17. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674-2678.
18. Crippa F, Leutner M, Belli F, et al. Which kinds of lymph node metastases can fdg-pet detect? A clinical study in melanoma. J Nucl Med. 2000;41:1491-1494.
19. Wagner JD Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol. 2001;77:237-242.
20. Wagner JD, Davidson D, Coleman JJ III, et al. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma. Ann Surg Oncol. 1999;6:398-404.